Displaying Results 61 - 66 of 66
Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses using adjuvant chemotherapy for elderly and frail patients. What was seen in particular in the trial performed by NCI Canada, using cisplatin with navelbine chemotherapy, was that people who were considered elderly were able to
GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
Dr. David Harpole, Duke University Medical Center, describes how he assists patients with the surgical decision-making process.
Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.
UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.